Objective To evaluate modified versions of the Belimumab International Study in Lupus Nephritis (BLISS-LN) belimumab study primary efficacy renal response (mPERR) and complete renal response (mCRR) ...

Belimumab combined with standard of care therapy is safe and effective for treating systemic lupus erythematosus. Belimumab combined with standard of care (SOC) therapy shows promising efficacy ...

Belimumab combined with standard of care (SOC) therapy shows promising efficacy and safety for the treatment of systemic lupus erythematosus (SLE), including lupus nephritis (LN), according to study ...

Objectives The study (206347) compared organ damage progression in patients with systemic lupus erythematosus (SLE) who received belimumab in the BLISS long-term extension (LTE) study with propensity ...

The new guideline also recommends faster tapering to a lower dose of glucocorticoids and a longer duration of ...

Benlysta (belimumab) is a brand-name injectable medication. It’s prescribed for systemic lupus erythematosus or lupus nephritis in certain adults and children. As with other drugs, Benlysta can ...

Among these, Bliss Roots CBD Gummies have emerged as a promising option, captivating the attention of those interested in harnessing the benefits of cannabidiol in a delicious and convenient form.

Bliss GVS Pharma Ltd., incorporated in the year 1984, is a Small Cap company (having a market cap of Rs 1,634.37 Crore) operating in Pharmaceuticals sector. Bliss GVS Pharma Ltd. key Products/Revenue ...